Enlivex Therapeutics Ltd (ENLV)

$1.16 0.00 (N/A)
Market Cap 275.36M
Revenue (ttm) 0.00
Net Income (ttm) -15.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 314,800
Avg Vol 804,716
Day's Range N/A - N/A
Shares Out 237.38M
Stochastic %K 63%
Beta 1.63
Analysts Sell
Price Target $13.00

Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 620 8072
Address:
14 Einstein Street, Ness Ziona, Israel
JimmyBobby49
JimmyBobby49 Feb. 6 at 1:59 PM
$ENLV Crypto drops and RAIN presses onward😎
0 · Reply
WebwallXii
WebwallXii Feb. 6 at 12:38 PM
$ENLV $VEEE $CCHH $ISPC next $ELPW
0 · Reply
BullButter23
BullButter23 Feb. 6 at 12:36 PM
Watchlist: $ELPW 👀 0 shares available to short Cost to borrow 701.60% $ENLV 0 shares available 442.67% CTB $VEEE 0 shares available 441.85% CTB $CCHH 0 shares available 216.82% CTB $LIMN 0 shares available 41.32%
0 · Reply
InvestForDaKids
InvestForDaKids Feb. 6 at 2:06 AM
$ENLV let’s go $88
0 · Reply
Safran18
Safran18 Feb. 5 at 7:32 AM
$ENLV
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 4:13 AM
$ENLV RSI: 65.75, MACD: 0.0538 Vol: 0.11, MA20: 0.99, MA50: 0.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jan. 31 at 6:44 PM
$ENLV crypto’s falling…
0 · Reply
Nicks_pics
Nicks_pics Jan. 30 at 10:13 PM
$ENLV It’s bio so charting is perhaps meaningless, but there is a cup and handle forming on the 3 month. Interesting to watch what happens. News coming??
1 · Reply
cled
cled Jan. 28 at 1:59 PM
$ENLV
0 · Reply
Safran18
Safran18 Jan. 28 at 8:01 AM
$ENLV keeps on adding
0 · Reply
Latest News on ENLV
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Jan 26, 2026, 8:00 AM EST - 12 days ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Jan 23, 2026, 8:00 AM EST - 15 days ago

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum

Jan 14, 2026, 11:46 AM EST - 24 days ago

Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Dec 4, 2025, 8:00 AM EST - 2 months ago

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Nov 24, 2025, 10:00 AM EST - 2 months ago

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Nov 24, 2025, 7:55 AM EST - 2 months ago

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nov 24, 2025, 6:40 AM EST - 2 months ago

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Oct 28, 2025, 8:15 AM EDT - 3 months ago

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Sep 29, 2025, 8:15 AM EDT - 4 months ago

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Sep 11, 2025, 8:00 AM EDT - 5 months ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Sep 9, 2025, 8:00 AM EDT - 5 months ago

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Aug 18, 2025, 7:45 AM EDT - 6 months ago

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Aug 14, 2025, 8:30 AM EDT - 6 months ago

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Jul 28, 2025, 8:30 AM EDT - 6 months ago

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Jun 10, 2025, 8:30 AM EDT - 8 months ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025, 8:00 AM EDT - 9 months ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 23, 2025, 8:30 AM EDT - 10 months ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 21, 2025, 8:30 AM EDT - 10 months ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 11 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 11 months ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 1 year ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 1 year ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Feb 18, 2025, 6:20 AM EST - 1 year ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jan 10, 2025, 9:00 AM EST - 1 year ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 11, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 1 year ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 26, 2024, 10:15 AM EST - 1 year ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nov 14, 2024, 8:00 AM EST - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 30, 2024, 9:00 AM EDT - 1 year ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

May 29, 2024, 4:15 PM EDT - 1 year ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

May 28, 2024, 8:12 AM EDT - 1 year ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Apr 16, 2024, 7:50 AM EDT - 1 year ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Apr 11, 2024, 2:58 PM EDT - 1 year ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Apr 11, 2024, 8:05 AM EDT - 1 year ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mar 22, 2024, 10:50 AM EDT - 2 years ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

UMAC

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Feb 26, 2024, 8:30 AM EST - 2 years ago

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Feb 21, 2024, 8:30 AM EST - 2 years ago

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Jan 17, 2024, 8:00 AM EST - 2 years ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Dec 20, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Jul 31, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

May 31, 2023, 8:04 AM EDT - 2 years ago

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

May 8, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Apr 19, 2023, 8:00 AM EDT - 3 years ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Enlivex Appoints Andrew Singer to its Board of Directors

Apr 17, 2023, 8:00 AM EDT - 3 years ago

Enlivex Appoints Andrew Singer to its Board of Directors

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Apr 14, 2023, 9:40 AM EDT - 3 years ago

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

JimmyBobby49
JimmyBobby49 Feb. 6 at 1:59 PM
$ENLV Crypto drops and RAIN presses onward😎
0 · Reply
WebwallXii
WebwallXii Feb. 6 at 12:38 PM
$ENLV $VEEE $CCHH $ISPC next $ELPW
0 · Reply
BullButter23
BullButter23 Feb. 6 at 12:36 PM
Watchlist: $ELPW 👀 0 shares available to short Cost to borrow 701.60% $ENLV 0 shares available 442.67% CTB $VEEE 0 shares available 441.85% CTB $CCHH 0 shares available 216.82% CTB $LIMN 0 shares available 41.32%
0 · Reply
InvestForDaKids
InvestForDaKids Feb. 6 at 2:06 AM
$ENLV let’s go $88
0 · Reply
Safran18
Safran18 Feb. 5 at 7:32 AM
$ENLV
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 4:13 AM
$ENLV RSI: 65.75, MACD: 0.0538 Vol: 0.11, MA20: 0.99, MA50: 0.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jan. 31 at 6:44 PM
$ENLV crypto’s falling…
0 · Reply
Nicks_pics
Nicks_pics Jan. 30 at 10:13 PM
$ENLV It’s bio so charting is perhaps meaningless, but there is a cup and handle forming on the 3 month. Interesting to watch what happens. News coming??
1 · Reply
cled
cled Jan. 28 at 1:59 PM
$ENLV
0 · Reply
Safran18
Safran18 Jan. 28 at 8:01 AM
$ENLV keeps on adding
0 · Reply
Ichigodoran
Ichigodoran Jan. 27 at 6:28 PM
$BGL $MMA $ENLV RedChip Spotlights the Future of Finance at Fintech & Digital Asset Treasury Strategy (DATS) Virtual Investor Conference on February 4 https://www.barchart.com/story/news/37250820/redchip-spotlights-the-future-of-finance-at-fintech-digital-asset-treasury-strategy-dats-virtual-investor-conference-on-february-4
0 · Reply
Avocado_smash
Avocado_smash Jan. 27 at 3:13 AM
$ENLV PT 1.37++
1 · Reply
Safran18
Safran18 Jan. 26 at 7:56 PM
$ENLV Schwab really saved me when restricted this at 0.67 .. it was a signal for me to load at the bank account
1 · Reply
Nicks_pics
Nicks_pics Jan. 26 at 7:26 PM
$ENLV Things have changed.
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jan. 24 at 6:55 PM
$ENLV Great week! Congrats all. And welcome to all our new traders from Israel.
0 · Reply
peepthestamp
peepthestamp Jan. 24 at 2:10 AM
$ENLV
0 · Reply
peepthestamp
peepthestamp Jan. 23 at 9:49 PM
$ENLV
0 · Reply
nick_m
nick_m Jan. 23 at 7:42 PM
$ENLV any news with reverse split? When is the vote?
2 · Reply
JimmyBobby49
JimmyBobby49 Jan. 23 at 7:36 PM
$ENLV Cool deal that they are now moving totally to the NASDAQ. Should enhance their exposure.
0 · Reply
InvestForDaKids
InvestForDaKids Jan. 23 at 1:45 PM
$ENLV let’s go
0 · Reply
InvestForDaKids
InvestForDaKids Jan. 23 at 5:25 AM
$ENLV let’s go moon
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jan. 22 at 7:19 PM
$ENLV buck land!! Here comes $AMZE $IOBT 🔋
0 · Reply